Find your path to Ritu
672 people in our graph share verified history with Ritu β schools, employers, funds. One of them is your warm intro.
About
Dr. Ritu Lal is CEO and Co-Founder of GEn1E Lifesciences Inc., a clinical-stage biotech company developing immunomodulatory therapies for rare and inflammatory diseases. With over 20 years of experience in the biotech and pharmaceutical industry, she has led preclinical and clinical development teams, filed more than 15 Investigational New Drug Applications across neurology, inflammation, virology, pain, and oncology, and worked on two compounds that received New Drug Application approvals (Kaletra for HIV and Horizant/Regnite for Restless Legs Syndrome and Post Herpetic Neuralgia). She holds a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland, a Master's in Pharmacology from the University of Arizona, and a Master's in Management from Stanford University's MSx (Sloan)
Founder at GEn1E LifesciencesYC S19
Intro paths
Ritu went through Y Combinator (Summer 2019) β any YC alum in your network can reach them through the YC community.
Their group partner at YC was Jared Friedman, YC Group Partner β the partner who ran GEn1E Lifesciences's batch and knows the company first-hand. YC profile β
In turn, Ritu can intro founders to GEn1E Lifesciences's investors below.
Experience
- GEn1E Lifesciences Inc.CEO and Co-Foundercurrent2018 β presentPalo Alto, CA
- Advisor to Drug, Device and Diagnostic CompaniesConsultant2013 β 2018Palo Alto
- Mallinckrodt Inc., Autoimmune and Rare Diseases UnitProject Team Leader2013 β 2015Hayward, CA and Ellicott City, MD
- XenoPort, Inc.Executive Director, Clinical Pharmacology, PK/ADME and Project Team Leader2005 β 2012Santa Clara, CA
- Roche Palo AltoDirector and Clinical Lead, Clinical Pharmacology1999 β 2005Palo Alto, CA
- Abbott LaboratoriesResearch Pharmacokineticist1996 β 1999Abbott Park, IL
Skills & more
+12 more
Clinical PharmacologyPharmacokineticsGCPToxicologyTranslational MedicineRegulatory SubmissionsR&DFormulationINDCROStrategyLeadershipLanguages English, Hindi
From Ritu's professional profile.
Frequently asked questions
- Who is Ritu Lal?
- Dr. Ritu Lal is CEO and Co-Founder of GEn1E Lifesciences Inc., a clinical-stage biotech company developing immunomodulatory therapies for rare and inflammatory diseases. With over 20 years of experience in the biotech and pharmaceutical industry, she has led preclinical and clinical development teams, filed more than 15 Investigational New Drug Applications across neurology, inflammation, virology, pain, and oncology, and worked on two compounds that received New Drug Application approvals (Kaletra for HIV and Horizant/Regnite for Restless Legs Syndrome and Post Herpetic Neuralgia). She holds a doctorate in Pharmaceutical Sciences and Pharmacology from the University of Maryland, a Master's in Pharmacology from the University of Arizona, and a Master's in Management from Stanford University's MSx (Sloan)
- Where does Ritu Lal work?
- Ritu Lal is Founder of GEn1E Lifesciences.
- What companies did Ritu Lal found?
- Ritu Lal founded GEn1E Lifesciences.
- Where did Ritu Lal go to school?
- Ritu Lal studied at Stanford University (Sloan Program, Masters in Management); University of Maryland School of Pharmacy (Doctor of Philosophy - PhD, Pharmaceutical Sciences); University of Arizona (Master of Science (M.S.), Pharmaceutical Sciences).
Founder mafias
Y Combinator mafia10,230
Also came through, then founded or led a company.
+ 10,223 more
Stanford University mafia1,934
Also came through, then founded or led a company.
+ 1,927 more
University of Arizona mafia85
Also came through, then founded or led a company.
+ 78 more
Mallinckrodt mafia5
Also came through, then founded or led a company.
Same school
Also attended Stanford University2,000
+ 1,994 more
Also attended University of Arizona260
+ 254 more
Shared employers
Also worked at GEn1E Lifesciences Inc.1
Also worked at Mallinckrodt Inc., Autoimmune and Rare Diseases Unit17
+ 11 more
Also worked at XenoPort, Inc.1
Also worked at Roche Palo Alto229
+ 223 more



.png)




































